SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults

Abstract Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022–June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2024-06, Vol.78 (6), p.1531-1535
Hauptverfasser:	Levy, Matthew E, Burrows, Evanette, Chilunda, Vanessa, Pawloski, Pamala A, Heaton, Phillip R, Grzymski, Joseph, Goldman, Jason D, McEwen, Lisa M, Wyman, Dana, Dei Rossi, Andrew, Dai, Hang, Isaksson, Magnus, Washington, Nicole L, Basler, Tracy, Tsan, Kevin, Nguyen, Jason, Ramirez, Jimmy, Sandoval, Efren, Lee, William, Lu, James, Luo, Shishi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Monophosphate - analogs & derivatives Adenosine Monophosphate - therapeutic use Adult Aged Alanine - analogs & derivatives Alanine - therapeutic use Antiviral Agents - therapeutic use COVID-19 - epidemiology COVID-19 Drug Treatment Cytidine - analogs & derivatives Female Humans Hydroxylamines Male Middle Aged Practice Patterns, Physicians' - statistics & numerical data Risk Factors Ritonavir - therapeutic use SARS-CoV-2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022–June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/ciad796